Cronobacter sakazakii: Are You Aligned With the FDA’s Recommendations?

In an effort to strengthen the infant formula supply chain's response to Cronobacter outbreaks, the FDA issued a call-to-action in March 2023 to enhance risk mitigation efforts.

Did you know that we offer a comprehensive suite of solutions and services that provides manufacturers with a complete set of augmented data that is in total alignment with the FDA’s call-to-action?

Download Our Infographic

Complete the form below to access the infographic, which will be sent directly to your email after submission. By providing your information, you agree to receive additional emails from bioMérieux about Cronobacter detection.

To find out more about the management of your personal data and to exercise your rights, see our privacy policy.

Additional Resources

CASE STUDY

From Insight to Action

We utilized our suite of tools and specialists to help the customer gain never-before-seen insights to effectively mitigate their persistent C. sakazakii challenge.

ACCESS CASE STUDY

OUR PORTFOLIO

Comprehensive Cronobacter Solutions

We help provide a complete set of augmented data that aligns with with the FDA’s recommendations, enabling more confident decisions from raw materials to finished products. Partner with bioMérieux to go beyond detection and fully understand the microbiome of your entire facility.

EXPLORE OUR OFFERING